1. Home
  2. TARS vs UGP Comparison

TARS vs UGP Comparison

Compare TARS & UGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TARS
  • UGP
  • Stock Information
  • Founded
  • TARS 2016
  • UGP 1937
  • Country
  • TARS United States
  • UGP Brazil
  • Employees
  • TARS N/A
  • UGP N/A
  • Industry
  • TARS Medicinal Chemicals and Botanical Products
  • UGP Oil/Gas Transmission
  • Sector
  • TARS Health Care
  • UGP Utilities
  • Exchange
  • TARS Nasdaq
  • UGP Nasdaq
  • Market Cap
  • TARS 2.8B
  • UGP 3.2B
  • IPO Year
  • TARS 2020
  • UGP 1999
  • Fundamental
  • Price
  • TARS $67.56
  • UGP $3.92
  • Analyst Decision
  • TARS Strong Buy
  • UGP Strong Buy
  • Analyst Count
  • TARS 7
  • UGP 2
  • Target Price
  • TARS $69.43
  • UGP $4.50
  • AVG Volume (30 Days)
  • TARS 613.1K
  • UGP 3.0M
  • Earning Date
  • TARS 11-04-2025
  • UGP 11-12-2025
  • Dividend Yield
  • TARS N/A
  • UGP 2.97%
  • EPS Growth
  • TARS N/A
  • UGP 2.46
  • EPS
  • TARS N/A
  • UGP 0.48
  • Revenue
  • TARS $295,521,000.00
  • UGP $25,352,989,456.00
  • Revenue This Year
  • TARS $139.46
  • UGP $6.09
  • Revenue Next Year
  • TARS $49.91
  • UGP $2.42
  • P/E Ratio
  • TARS N/A
  • UGP $7.82
  • Revenue Growth
  • TARS 254.45
  • UGP 7.38
  • 52 Week Low
  • TARS $38.51
  • UGP $2.53
  • 52 Week High
  • TARS $76.81
  • UGP $4.16
  • Technical
  • Relative Strength Index (RSI)
  • TARS 54.32
  • UGP 54.62
  • Support Level
  • TARS $65.30
  • UGP $3.86
  • Resistance Level
  • TARS $74.83
  • UGP $3.93
  • Average True Range (ATR)
  • TARS 2.87
  • UGP 0.09
  • MACD
  • TARS -0.99
  • UGP -0.01
  • Stochastic Oscillator
  • TARS 19.64
  • UGP 59.52

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

About UGP Ultrapar Participacoes S.A.

Ultrapar Participacoes SA engages in the investment of its own capital in services, commercial, and industrial activities, through the subscription or acquisition of shares of other companies. The Company has three business segments: Ultragaz distributes LPG in the segments: bulk, comprising condominiums, trade, services, industries, and agribusiness; and bottled, mainly comprising residential consumers. The Ipiranga engages in the distribution and sale of oil-related products, biofuels, and similar products to service stations that operate under the Ipiranga brand throughout Brazil and to consumers and carrier-reseller-retailer. The Ultracargo operates in specialized liquid bulk storage solutions in the main logistics centers of Brazil.

Share on Social Networks: